ROTE WILLIAM E. 4
4 · Travere Therapeutics, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
ROTE WILLIAM E.
Chief Research Officer
Transactions
- Sale
Common Stock
2025-01-22$19.46/sh−2,437$47,424→ 83,170 total
Footnotes (2)
- [F1]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F2]Includes 1,152 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.